C Alzieu
Overview
Explore the profile of C Alzieu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
172
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Genre D, Protiere C, Gravis G, Camerlo J, Alzieu C, Maraninchi D, et al.
Support Care Cancer
. 2002 Mar;
10(3):222-30.
PMID: 11904787
This study was designed to measure treatment side-effects and quality of life (QL) of 47 nonmetastatic breast cancer patients subjected to a dose-intensity increase while receiving a sequential high dose...
2.
Resbeut M, Alzieu C, Gonzague-Casabianca L, Badinand D, Bardou V, Cravello L, et al.
Int J Radiat Oncol Biol Phys
. 2001 Jun;
50(4):873-81.
PMID: 11429214
Purpose: The aim of this retrospective study was to evaluate the survival data and rates and patterns of complications and recurrences for patients who had early uterine cervix carcinoma and...
3.
Cutuli B, Borel C, Dhermain F, Magrini S, Wasserman T, Bogart J, et al.
Radiother Oncol
. 2001 May;
59(3):247-55.
PMID: 11369065
Purpose: To assess the clinical and histological characteristics of breast cancer (BC) occurring after Hodgkin's disease (HD) and give possible therapies and prevention methods. Materials And Methods: In a retrospective...
4.
Alzieu C
Sci Total Environ
. 2000 Sep;
258(1-2):99-102.
PMID: 11007281
The deleterious effects of TBT released by antifouling paints were first documented in Arcachon Bay (France) at the end of the 1970s. As a result of the high level of...
5.
Resbeut M, Haie-Meder C, Alzieu C, Gonzague-Casabianca L
Cancer Radiother
. 2000 May;
4(2):140-6.
PMID: 10812360
Low-stage uterine cervix carcinoma can be treated by either surgery, radiation therapy or combined treatments with high cure rates ranging from 90 to 95% for stage IB1 tumors. However, the...
6.
Bouabdallah R, Coso D, Gonzague-Casabianca L, Alzieu C, Resbeut M, Gastaut J
Leuk Res
. 2000 Apr;
24(6):491-5.
PMID: 10781683
Splenic irradiation in idiopathic myelofibrosis (IMF) has often been use d in selected situations when other therapies were unefficient or contraindicated. This could improve quality of life of patients, but...
7.
Protiere C, Viens P, Genre D, Cowen D, Camerlo J, Gravis G, et al.
Ann Oncol
. 2000 Feb;
11(1):39-45.
PMID: 10690385
Background: Shared decision-making is increasingly advocated as an ideal model. However, very few studies have tested the feasibility of giving patients the opportunity to participate in the choice of treatment....
8.
Cutuli B, Janvier M, De La Rochefordiere A, Julien J, Isambert N, Alzieu C, et al.
Presse Med
. 2000 Feb;
29(3):135-8.
PMID: 10686962
Objective: The purpose of this study was to determine the clinical and prognostic features of leukemias and preleukemic states, whatever the mode of development, observed in patients after treatment of...
9.
Gravis G, Viens P, Alzieu C, Camerlo J, Jausseran M, Maraninchi D
Anticancer Drugs
. 1999 Jun;
10(4):369-74.
PMID: 10378671
Preclinical and clinical data have suggested antitumor efficacy in squamous cell carcinoma (SCC) of interferon (IFN)-alpha and 13-cis-retinoic acid (13-c-RA) as single agent with greater activity in combination. Cisplatin was...
10.
Bouabdallah R, Stoppa A, Rossi J, Lepeu G, Coso D, Xerri L, et al.
Leukemia
. 1999 Jun;
13(6):950-6.
PMID: 10360385
We previously reported feasibility and efficacy of a monocentric pilot study of intensive sequential chemotherapy (ISC) in poor-risk aggressive non-Hodgkin's lymphoma (NHL) in patients < 60 years. To validate these...